Biophytis (BPTS) Stock
BPTS is no longer traded. Biophytis was delisted from the Nasdaq in June 2024.
Prices on this page are historical; the last trade was June 27, 2024 at $7.03.
Biophytis stock price history
BPTS final trading statistics
- Final close
- $7.03
- Final trading day
- Jun 27, 2024
- Market cap at delisting
- $2.01M
- Shares outstanding
- 0.29M
- Final 52-week range
- $0.27 – $11.20
- Avg. volume (final 3 mo.)
- 8,150
- All-time high (split-adj.)
- $6808.00 · Feb 2021
- All-time low (split-adj.)
- $5.92 · Jun 2024
- Return since IPO
- -99.9%
- Beta
- 1.05
- Book value / share
- -$0.00
- Price / book
- -1757.50
Biophytis annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$17.0M | — |
| FY2022 | $0.00 | -$22.7M | $0.00 |
| FY2021 | $0.00 | -$33.5M | -$0.07 |
| FY2020 | $0.00 | -$21.4M | -$0.45 |
| FY2019 | $0.00 | -$17.8M | -$1.23 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Biophytis
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Biophytis stock FAQ
What happened to Biophytis stock?
Biophytis stock was delisted from the Nasdaq. Its final close was $7.03 on June 27, 2024.
Is BPTS stock still trading?
No. BPTS was delisted from the Nasdaq in June 2024 and no longer trades on a U.S. exchange.
What was the last price of BPTS stock?
BPTS closed at $7.03 on its final trading day, June 27, 2024, for a market value of about $2.01M.
What were Biophytis's revenue and earnings in its last full fiscal year?
Biophytis reported revenue of $0.00 and net income of -$17.0M in fiscal 2023, its last full year as a public company.
When did Biophytis go public?
Biophytis stock began trading on February 10, 2021.